Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126180264 | 12618026 | 4 | F | 20160731 | 20160906 | 20160803 | 20160913 | EXP | PHHY2016PA106190 | NOVARTIS | 89.00 | YR | F | Y | 0.00000 | 20160913 | CN | PA | PA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126180264 | 12618026 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 18 MG/10 CM2 PATCH | U | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 126180264 | 12618026 | 2 | C | IRBESARTAN. | IRBESARTAN | 1 | Oral | 300 MG, QD | U | 0 | 300 | MG | TABLET | QD | |||||
| 126180264 | 12618026 | 3 | C | CORYOL | CARVEDILOL | 1 | Oral | 6.25 MG, QD | 0 | 6.25 | MG | TABLET | QD | ||||||
| 126180264 | 12618026 | 4 | C | VERAPAMIL | VERAPAMIL HYDROCHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 126180264 | 12618026 | 5 | C | PERINDOPRIL | PERINDOPRIL | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126180264 | 12618026 | 1 | Dementia Alzheimer's type |
| 126180264 | 12618026 | 2 | Hypertension |
| 126180264 | 12618026 | 3 | Product used for unknown indication |
| 126180264 | 12618026 | 4 | Hypertension |
| 126180264 | 12618026 | 5 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126180264 | 12618026 | OT |
| 126180264 | 12618026 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126180264 | 12618026 | Aggression | |
| 126180264 | 12618026 | Agitation | |
| 126180264 | 12618026 | Asthma | |
| 126180264 | 12618026 | Cardiac failure | |
| 126180264 | 12618026 | Dementia Alzheimer's type | |
| 126180264 | 12618026 | Dysuria | |
| 126180264 | 12618026 | Insomnia | |
| 126180264 | 12618026 | Memory impairment | |
| 126180264 | 12618026 | Nasopharyngitis | |
| 126180264 | 12618026 | Nervousness | |
| 126180264 | 12618026 | Oedema peripheral | |
| 126180264 | 12618026 | Pulmonary oedema | |
| 126180264 | 12618026 | Speech disorder | |
| 126180264 | 12618026 | Urinary tract infection | |
| 126180264 | 12618026 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |